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ABSTRACT: Down syndrome (DS) is one of the most common genetic causes of intellectual disability and is 
characterized by a number of behavioral as well as cognitive symptoms. Many of the neuropathological features 
of early-onset Alzheimer’s disease (AD) including senile plaques and neurofibrillary tangles (NFTs) are also 
present in people with DS as a result of triplication of the amyloid precursor gene on chromosome 21. Evidence 
suggests that harboring one or both apolipoprotein E4 (APOE4) alleles may increase the risk for AD due to the 
proteolytic cleavage of apoE4 and a subsequent loss of function. To investigate a role for the apoE proteolysis 
in vivo, we compared three autopsy groups; 7 DS with AD neuropathology cases over 40 years, 5 young DS 
cases without AD pathology under 40 years (YDS) and 5 age-matched control cases over 40 years by 
immunohistochemistry utilizing an antibody that detects the amino-terminal fragment of apoE. Application of 
this antibody, termed the amino-terminal apoE fragment antibody (nApoECF) revealed labeling of pyramidal 
neurons in the frontal cortex of YDS cases, whereas in the DS-AD group, labeling with nApoECF was 
prominent within NFTs. NFT labeling with nApoECF was significantly greater in the hippocampus versus the 
frontal cortex in the same DS-AD cases, suggesting a regional distribution of truncated apoE. Colocalization 
immunofluorescence experiments indicated that 52.5% and 53.2% of AT8- and PHF-1-positive NFTs, 
respectively, also contained nApoECF. Collectively, these data support a role for the proteolytic cleavage of 
apoE in DS and suggest that apoE fragmentation is closely associated with NFTs. 
Key words: Alzheimer’s disease, beta-amyloid, paired helical filaments, proteolysis, neurofibrillary tangles, 
immunohistochemistry 
 
 
 
 
Down syndrome (DS) is a chromosomal disorder 
(Trisomy 21) that is caused by nondisjunction resulting in 
the triplication of the chromosome 21 in the large majority 
of cases and is the most commonly identified genetic 
cause of intellectual disability in the United States [1, 2].  
In addition to several phenotypic features of DS [3-7], 
people with DS also exhibit mild to moderate cognitive 
dysfunction [8] delayed verbal short-term memory and 
neurobehavioral problems [9].  In addition to the 
phenotypic and cognitive impairments associated with 
this disorder, an increased risk of Alzheimer’s disease 
(AD) in patients with DS is also well established.  In DS, 
the postmortem findings of senile plaques and 
neurofibrillary plaques (NFTs) is assumed to be caused by 
the overexpression of the amyloid precursor protein 
(APP) following triplication of chromosome 21 and 
accumulation of beta-amyloid.  In DS, nearly all adults 
over 35 to 40 years of age exhibit key neuropathological 
changes characteristic of AD including the formation of 
extracellular plaques of beta-amyloid and NFTs [10-12].  
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Previous studies have shown a substantial increase in 
the cumulative incidence of dementia in adults with DS 
between ages 50 and 72 [13]. Risk factors that affect the 
age of onset of dementia in DS include harboring the 
APOE4 allele as well as high levels of plasma beta-
amyloid 1-42 [14].  In contrast, there is a reduced risk for 
the onset of dementia associated with APOE2 allele and 
atypical karyotypes in DS [14]. The human APOE gene is 
polymorphic resulting in three major isoforms, apoE2, 
apoE3, and apoE4, which differ by single amino acid 
substitutions involving cysteine-arginine replacements at 
positions 112 and 158 [15].  Inheritance of one copy of 
the APOE4 allele increases the disease risk of AD four-
fold, while two copies enhances disease risk 
approximately ten-fold [16].  Thus, harboring the APOE4 
allele represents the most significant late-onset genetic 
risk factor.  A recent study highlighted this risk by 
demonstrating that the lifetime risk of AD at the age of 85 
without reference to the APOE genotype was 11% in 
males and 14% in females [17]. At the same age, this risk 
ranged from 51% for APOE 4/4 male carriers to 60% for 
APOE 4/4 female carries, consistent with a semi-
dominant inheritance pattern [17]. The preponderance of 
evidence suggests that harboring the APOE4 allele in DS 
also increases AD disease risk, although to a lower extent 
to what has been found in AD [18]. Additionally, studies 
suggest harboring the APOE4 allele leads to earlier 
mortality in the DS population that is independent of the 
risk of dementia [19, 20].  How apoE4 increases the risk 
for AD is unknown, however, evidence suggests that the 
enhanced susceptibility of apoE4 to proteolysis as 
compared to E2 and E3 may play a critical role leading to 
loss of function including impaired cholesterol transport 
and beta-amyloid clearance [21]. The purpose of the 
current study was to investigate whether apoE proteolysis 
is prevalent in postmortem DS human brain sections 
utilizing an antibody that detects the amino-terminal 
fragment of apoE (herein termed, nApoECF antibody) 
[22]. Previous studies carried out with the nApoECF 
antibody demonstrated that it consistently labeled NFT’s 
in sporadic AD, Picks disease and vascular dementia in 
addition to the labeling of blood vessels and reactive 
astrocytes [22-24].  Our findings using the nApoECF 
antibody in the present study support a role for the 
proteolytic cleave of apoE with aging and AD in DS and 
suggest that apoE fragmentation is closely associated with 
mature NFTs. 
 
 
 
Table 1. Case Demographics 
 
Case NPD Sex PMI Age Region Cause of Death APOE Genotype 
1 Normal F 24 46 Frontal Cortex Multiple injuries N/A 
2 Normal F 21 51 Frontal Cortex Cardiovascular disease N/A 
3 Normal M 17 57 Frontal Cortex Arteriosclerotic 
cardiovascular disease 
N/A 
4 Normal M 5 65 Frontal Cortex Cardiac arrest N/A 
5 Normal M 3 67 Frontal Cortex Cardiomyopathy N/A 
6 YDS M 24 24 Frontal Cortex Cardiac arrhythmia N/A 
7 YDS M 4 31 Frontal Cortex Pneumonia N/A 
8 YDS F 36 34 Frontal Cortex 
and Hippocampus 
Septic shock N/A 
9 YDS F 12 39 Frontal Cortex 
and Hippocampus 
Cancer N/A 
10 YDS M 5 33 Frontal Cortex 
and Hippocampus 
Acute bronchopneumonia N/A 
11 DS-AD M 6 46 Frontal cortex and 
Hippocampus 
Cardiac respiratory failure 2/3 
12 DS-AD M 18 56 Frontal cortex and 
Hippocampus 
Alzheimer’s disease 3/3 
13 DS-AD F 5 57 Frontal cortex and 
Hippocampus 
Other 3/3 
14 DS-AD M 10 66 Frontal Cortex Congestive heart failure N/A 
15 DS-AD M 2 67 Frontal Cortex Pneumonia N/A 
16 DS-AD F 3 57 Hippocampus Alzheimer’s disease 3/3 
17 DS-AD M 2.2 49 Hippocampus Pneumonia 3/3 
 
PMI, postmortem interval in hours; NPD, neuropathological diagnosis; YDS, young Down Syndrome; DS-AD, Down syndrome with Alzheimer’s 
disease pathology. For all DS-AD cases, the Braak & Braak staging was VI/C. 
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MATERIALS AND METHODS 
 
Subjects 
 
Autopsy brain tissue was obtained from three groups – 
Young DS (YDS), DS with sufficient neuropathology for 
AD (DS-AD) and age matched controls for the DS-AD 
cases. Case demographics are presented in Table 1. Fixed 
hippocampal tissue sections used in this study were 
provided by either the Institute for Memory Impairments 
and Neurological Disorders at the University of 
California, Irvine or the NIH NeuroBioBank. Approval 
from Boise State University Institutional Review Board 
was not obtained due to the exemption granted that all 
tissue sections were fixed and received from University of 
California, Irvine. Brain tissue obtained from University 
of California, Irvine were anonymized and never 
identified except by case number. Tissue donors or their 
next of kin provided informed signed consents to the 
Institute for Memory Impairments and Neurological 
Disorders for the use of their tissues in research (IRB 
2014-1526). AD was established in DS cases based upon 
published consensus neuropathological criteria [25]. 
 
Immunohistochemistry 
 
Free-floating 40 μm-thick sections were used for bright-
field immunohistochemical studies as previously 
described [23]. The primary antibody was visualized 
using brown DAB substrate (Vector Laboratories).  
 
Immunofluorescence Microscopy 
 
Primary antibodies utilized included PHF-1 (mouse 
monoclonal, 1:1,000), AT8 (mouse monoclonal, 1:250) 
and nApoECF (rabbit monoclonal, 1:100).  PHF-1 was a 
generous gift from Dr. Peter Davies (Albert Einstein 
College of Medicine, Bronx, NY). The AT8 antibody was 
purchased from Pierce, ThermoFisher Scientific Inc. 
(Waltham, MA).  The anti-apoE4 full-length C-terminal 
mouse antibody was purchased from Abgent (San Diego, 
CA).  The anti-apoE4 full-length N-terminal mouse 
antibody was purchased from Aviva Systems Biology 
Corp. (San Diego, CA). No antigen retrieval methods 
were employed. For double-label immunofluorescence 
co-localization studies, experiments were conducted as 
previously described [23].  Briefly, an Olympus BX60 
microscope with fluorescence capability equipped with a 
MagnaFire SP software system for photomicrography was 
employed for microscopic observation and 
photomicrography of the DAB-labeled and fluorescent 
sections. The fluorescent molecules were excited with a 
100-W mercury lamp. Fluorescent-labeled molecules 
were detected using a filter set having a 460-500-nm 
wavelength band pass excitation filter, a 505-nm dichroic 
beam splitter, and a 510-560-nm band pass emission filter.  
 
Confocal microscopy  
 
Confocal immunofluorescence imaging was as previously 
described [23], and primary antibodies were visualized 
with secondary antibodies tagged with either Alexa Fluor 
488 or Alexa Fluor 555 (Invitrogen, Carlsbad, CA). 
Images were taken with a Zeiss LSM 510 Meta system 
combined with the Zeiss Axiovert Observer Z1 inverted 
microscope and ZEN 2009 imaging software (Carl Zeiss, 
Inc., Thornwood, NY). Confocal Z-stack and single plane 
images were acquired with an Argon (488 nm) and a 
HeNe (543 nm) laser source. Z-stacks images were 
acquired using a 20x Plan-Apochromat (NA 0.8) 
objective, emission band passes of 505-550 nm for the 
detection of the nApoECF (green channel, Alexa Fluor 
488) and 550-600 nm for detection of PHF-1 (red channel, 
Alexa Fluor 555).  All images displayed are 2-D, maximal 
intensity projections generated acquired Z-stacks. The 
optical depth used varied between experiments but was in 
the range of 10-25 µm in the Z-plane.  Single plane images 
were acquired with a 63x Plan-Apochromat oil-
immersion objective (NA 1.4) with emission long pass of 
505 nm for the detection of the nApoECF antibody (green 
channel, Alexa Fluor 488) and 550-600 nm for the 
detection of PHF-1 (red channel, Alexa Fluor 555).  
 
Statistical analysis 
 
To determine significant differences between the various 
cohorts, an ANOVA was used to test for group differences 
in cell counts.  IBM SPSS Statistics (Ver. 22) was used 
for statistical analyses with an alpha level of 0.05. 
To determine the percent co-localization, a 
quantitative analysis was performed as described 
previously [23] by taking 20X immunofluorescence, 
overlapping images from three different fields in area 
CA1 in three separate DS-AD cases. Capturing was by 
using a 2.5x photo eyepiece, and a Sony high resolution 
CCD video camera (XC-77). For example, to determine 
the percent co-localization between nApoECF and PHF-
1, photographs were analyzed by counting the number of 
nApoECF or PHF-1-positive NFTs alone per 20X field 
for each case, and the number of cells labeled with both 
PHF-1 and nApoECF. Data are representative of the 
average number (±S.D.) of each antibody alone or co-
localized with both antibodies in each 20X field (3 fields 
total for 4 different cases). Statistical differences in this 
study were determined using Student’s two-tailed T-test 
employing Microsoft Office Excel. We used the 
Kolmogorov-Smirnov test of normality (SPSS Statistics) 
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and all groups were normally distributed and thus, it was 
appropriate to use an ANOVA for the analysis.  To 
determine any possible correlations between the various 
groups, Pearson’s coefficients were determined using 
Microsoft Office Excel.  
 
 
 
 
Figure 1. Localization of an amino-terminal fragment of apoE in the frontal cortex of Down’s syndrome. 
(A-B): Application of the nApoECF antibody in frontal cortex tissue sections from YDS cases revealed labeling 
predominantly within pyramidal neurons (arrows, low magnification Panel A) and (arrows, high magnification 
Panel B).  (C): In contrast, in DS-AD cases, in addition to neuronal staining, more mature, fibrillary NFTS were 
labeled with the nApoECF antibody (arrows), whereas little immunoreactivity was observed in age-matched 
control cases (D).    (E): A least significant difference post hoc test analysis of the number of nApoECF-positive 
neurons and NFTs in frontal cortex indicated a significant difference between DS-AD cases and age-matched 
controls (p= 0.02) and YDS groups (p = 0.05). For all three groups, n = 5, ±S.E.M.  All scale bars represent 10 µm 
except for Panel D, which represents 50 µm. 
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Figure 2. Localization of an amino-terminal fragment of apoE in the hippocampus of Down’s syndrome. 
Application of the nApoECF antibody in hippocampal tissue sections revealed very little labeling in YDS cases (A) or 
in age-matched controls (C), however, strong immunolabeling of NFTs was observed in DS-AD cases (B). (D): Three 
DS-AD cases were quantified (±S.D.) for the number of nApoECF-positive NFTs comparing hippocampal versus frontal 
cortex regions.  The data revealed a clear difference between the numbers of labeled NFTs between the two regions with 
the hippocampus giving consistently higher numbers.  Case #1, #2, and #3 correspond to subjects 13, 12, and 11, 
respectively, as listed in Table 1.  All scale bars for Panels A and C represent 50 µm and 10 µm for Panel D. 
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RESULTS 
 
Localization of the amino terminal fragment of apoE in 
the frontal cortex of Down’s syndrome  
 
To investigate a role for the apoE proteolysis in DS, an 
immunohistochemical study utilizing our in house 
nApoECF antibody was performed in fixed frontal cortex 
and hippocampal brain sections from 7 adult DS-AD 
cases, 5 YDS cases, and 5 neuropathogically normal 
cases.  Case demographics for the DS-AD, YDS and 
control groups are presented in Table 1. Age at death 
between the control and DS-AD groups was not 
statistically different (57.2 ±8.96 vs. 56.9 ±7.82). As an 
initial step, we screened all cases for nApoECF 
immunoreactivity using bright field microscopy.  
Previous characterization of this nApoECF antibody has 
indicated it to be highly specific for a neoepitope ~18 kDa 
amino-terminal fragment of apoE [22]. This in house 
antibody was synthesized based upon a putative protease-
cleavage site at position D172 of the full-length protein 
and has been extensively characterized biochemically to 
show that it does not react at all with the full-length form 
of apoE [22]. Application of this antibody to YDS frontal 
cortex brain sections revealed specific localization 
predominantly within pyramidal neurons (Figure 1A, 
arrows and 1B).  By contrast, application of the same 
antibody revealed labeling of both mature fibrillary NFTs 
(Figure 1C arrows) as well as neuronal staining in DS-
AD, while minimal immunoreactivity was observed in 
normal control cases (Figure 1D).  Quantitative analysis 
of labeled neurons and NFTs in the frontal cortex 
indicated that there was a significant main effect of group 
on cell counts with controls having the fewest positive 
cells, the young DS having an intermediate number of 
cells and the DS-AD cases having the highest number of 
positive cells (F(2, 14)=4.08 p=0.044). A significant 
difference was found between the age-matched controls 
and DS-AD group (p= 0.02) as well as between the YDS 
and DS-AD group (p= 0.05) (Figure 1E). 
 
Localization of the amino terminal fragment of apoE in 
the hippocampus of Down’s syndrome 
 
To determine if nApoECF labeling was specific to the 
frontal cortex similar experiments were conducted on 
hippocampal sections.  In contrast to what was observed 
in frontal cortex sections, application of the nApoECF 
antibody to hippocampal sections revealed little to no 
immunoreactivity in YDS and normal control cases 
(Figure 2A and 2C).  As observed in the frontal cortex 
cases, there was strong immunolabeling of NFTs as well 
as neuronal staining in DS-AD cases (Figure 2B).  To 
verify the observed differences between hippocampal and 
frontal cortex regions three DS-AD cases were quantified 
for the number of nApoECF-positive NFTs (Figure 2D).  
The results indicated that between the two regions the 
hippocampus consistently had higher numbers of labeled 
NFTs, suggesting a regional distribution of truncated 
apoE. The three cases used in this experiment were 
subjects 11 (case #3), 12 (case #2), and 13 (case #1) 
(Figure 2D) (Table 1). It is noteworthy that the APOE 
allele status for cases 12 and 13 was 3/3, while that for 
case 11 was 2/3 (Table 1). The data indicated a 
significantly higher number of identified nApoECF-
positive NFTs in the hippocampus of the APOE allele 3/3 
cases in comparison to the 2/3 case (Figure 2D).  
 
Co-localization of the nApoECF antibody within NFTs 
in hippocampal sections of the Down’s syndrome brain 
 
To determine the extent of co-localization of the 
nApoECF antibody, double-label immunofluorescence 
studies were performed using standard NFT tangle 
markers, PHF-1 and AT8 in fixed hippocampal brain 
sections.  The antibody AT8 recognizes tau 
phosphorylated at both serine 202 and threonine 205, 
which are the first residues to be hyperphosphorylated, 
whereas the antibody PHF-1 recognizes phosphorylation 
at serine 396 and 404 and reacts with more mature 
hyperphosphorylated forms of tau found primarily within 
late-stage tangles [26-28]. Confocal immunofluorescence 
microscopy revealed strong co-localization between the 
nApoECF antibody and PHF-1 in the hippocampus 
(Figure 3A-C).  Additionally, co-localization between 
nApoECF and the AT8 antibody was also evident, 
however, co-localization between the two appeared to be 
in distinct subcellular locations within the same tangle 
bearing neurons (Figure 3D-F).  Quantification of NFTs 
double-labeled by PHF-1 or AT8 and nApoECF revealed 
that roughly 52.5% of AT8-positive tangle bearing 
neurons contained nApoECF (Pearson coefficient = -
0.61), whereas 53.2% of all identified PHF-1-positive 
neurons were labeled with nApoECF (Pearson coefficient 
= 0.64) (Figure 3G-H). 
 
Co-localization of nApoECF with full-length amino 
terminal antibodies to apoE4 in NFTs of the Down 
syndrome brain 
 
Further double-label immunofluorescence studies were 
performed utilizing an antibody specific to the amino-
terminal region of full-length apoE4 and nApoECF 
(Figure 4A-C) in fixed hippocampal brain sections.  
Results showed strong co-localization within an apparent 
NFT (arrow, Panel C) as well as blood vessels 
(arrowhead, Panel C).  By contrast, application of a full-
length antibody specific for the C-terminal end of apoE4 
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strongly labeled blood vessels (Figure 4D, green) but 
resulted in a lack of immunoreactivity and co-localization 
with nApoECF within apparent NFTs (Figure 4D, 
arrows). The DS-AD cases used for these experiments are 
listed in Table 1 (11-13). 
 
 
 
 
 
Figure 3. Co-localization of an amino-terminal fragment of apoE within NFTs in hippocampal tissue sections of the Down’s 
syndrome brain.  (A-C): Representative confocal immunofluorescence double-labeling utilizing the nApoECF antibody (green, Panel 
A) and PHF-1 (red, Panel B) revealed strong co-localization of the two antibodies within a NFT located in the hippocampus (Panel C).  
(D-F): Identical to Panels A-C with the exception of AT8 (red) being employed.  For Panels A-F, images were captured from the CA1 
region of the hippocampus in representative DS-AD cases. (G and H): Quantification of NFTs double-labeled by PHF-1, AT8, and 
nApoECF. For both panels, data show the number of NFTs labeled with nApoECF alone (blue bar), AT8 (G) or PHF-1 (H) alone (green 
bars) or those NFTs that were labeled with both antibodies (red bars). NFTs were identified in a 20X field within hippocampal tissue 
sections by immunofluorescence overlap microscopy (n=3 fields using three different DS cases) ±S.E.M.  For Panel G there were no 
statistical differences between the various test groups. Data indicated that roughly 52.5% of AT8-positive NFTs also contained 
nApoECF, whereas 53.2% of all identified PHF-1-positive NFTs were labeled with nApoECF.  
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Figure 4. Co-localization of nApoECF with a full-length amino-terminal antibody to apoE4 in NFTs of the Down Syndrome 
brain. (A-C): Representative confocal immunofluorescence double-labeling in CA1 region of the hippocampus in DS-AD cases 
utilizing an antibody that recognizes the amino-terminal region of full-length apoE4 (green, A) and nApoECF (red, B), with the overlap 
image shown in Panel C. Strong co-localization was indicated in both apparent NFTs and blood vessels (yellow, C). (D): In contrast, no 
co-localization with nApoECF was observed in a similar experiment using a full-length antibody to the C-terminal end of apoE4, which 
strongly labeled blood vessels (green, D), but not NFTs (arrows, D). 
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DISCUSSION  
 
Harboring the APOE4 allele enhances the risk for AD and 
several reports have suggested that the proteolytic 
cleavage of apoE4 into N- and C-terminal fragments may 
provide a mechanism by which this protein contributes to 
AD pathogenesis (for recent review, see [21]). ApoE4 is 
highly susceptible to proteolysis compared to apoE3, and 
apoE4 fragments (14–20 kDa) have been identified in the 
AD brain [22, 29, 30]. However, whether apolipoprotein 
E4 contributes to an earlier onset of dementia or increased 
mortality in DS patients is still a matter of debate. Due to 
the location of the amyloid precursor protein on 
chromosome 21, many of the neuropathological features 
of early-onset AD including senile plaques and 
neurofibrillary tangles are also present in people with DS 
who are either demented or nondemented. Significant 
advances in medical treatment have increased longevity 
in people with DS resulting in an increased population that 
may be vulnerable to many of the same risk factors as 
those with sporadic AD.  Few genetic risk factors 
associated with late onset AD carry a larger risk potential 
for AD than that of the APOE4 allele.  Inheritance of one 
copy of the allele increases risk four-fold while 
inheritance of two copies increases risk ten-fold [16]. The 
preponderance of evidence suggests that harboring the 
APOE4 allele also increases dementia risk in DS, albeit to 
a lower extent than what is observed in AD [18]. 
Therefore, we sought to investigate whether apoE 
proteolysis is prevalent in postmortem DS human brain 
sections utilizing an in house antibody that detects the 
amino-terminal fragment of apoE. In AD this antibody, 
termed the amino-terminal apoE cleavage-fragment 
(nApoECF) antibody, predominantly labeled NFTs and 
co-localized with other tangle markers including AT8 and 
PHF-1 [22]. It is noteworthy that in AD, the nApoECF 
antibody is known to recognize fragmented E3 and E4 
[22]. In the present study utilizing the nApoECF antibody, 
we examined fixed frontal cortex and hippocampal brain 
sections from seven adult DS-AD cases.  An important 
caveat of the present study was the limited clinical 
information available regarding the APOE allele status of 
the patients used in this study. Therefore, we were unable 
to evaluate our findings in terms of APOE4 status.  
Application of this antibody to frontal cortex tissues 
revealed labeling of mature NFTs as well as neuronal 
staining in DS-AD, while staining was restricted to 
pyramidal neurons in YDS cases.  Not surprisingly, we 
did not observe labeling of NFTs in our YDS group as this 
is an age when NFTs are typically not present.  
Interestingly, in addition to NFTs, the nApoECF 
antibody also labeled neurons in both frontal and 
hippocampal regions. In this regard, there was a 
significant difference in the number of labeled neurons in 
controls versus the DS-AD group and the YDS versus the 
DS-AD group. In general, labeled neurons 
morphologically appeared normal as compared to NFTs. 
In contrast, minimal immunoreactivity was observed in 
age-matched control cases.  Results of experiments on 
hippocampal sections revealed little to no 
immunoreactivity in YDS and age matched control cases, 
and strong immunolabeling of NFTs as well as neuronal 
staining in DS-AD similar to what was seen in frontal 
cortex.  
Another finding in the present study was the 
significant difference in the number of labeled nApoECF-
NFTs in the hippocampus versus frontal cortex in the DS-
AD group. There was significantly higher number of 
labeled NFTs in the hippocampus as compared to frontal 
cortex. This suggests the appearance of the fragmentation 
of ApoE coincides with the normal progression of NFT 
pathology from the hippocampus to the frontal cortex that 
is a well-characterized finding in AD [31]. Alternatively, 
the data could imply that in these three cases, there were 
substantially more NFTs present in the hippocampus as 
compared to the frontal cortex as this analysis was not 
performed. For these experiments, the APOE genotype of 
two of the three cases was 3/3, while that of the third was 
2/3. The data indicated a significantly higher number of 
identified nApoECF-positive NFTs in the hippocampus of 
the 3/3 cases in comparison to the DS-AD 2/3 case (Figure 
2D).  These results would seem to support previous 
studies demonstrating that apoE2 is the most stable 
isoform [32] and may provide a rationale as to the 
protective role of harboring the APOE2 allele in 
preventing dementia [33]. 
To further characterize the labeling of nApoECF 
within NFTs, double-label immunofluorescence confocal 
studies were performed using PHF-1 and AT8 antibodies. 
Results showed strong co-localization between the 
nApoECF antibody and PHF-1 as well as AT8 in 
hippocampal sections. With respect to AT8, our results 
suggested that even though the two antibodies co-
localized within the same tangle bearing neurons, they 
appeared to be spatially separated.  This was in contrast to 
PHF-1, where strong overlap with nApoECF was 
observed. In addition, statistical analysis revealed a 
negative correlation between AT8 and nApoECF (-0.61), 
while a positive correlation was found between PHF-1 
(0.64). These data are suggestive that nApoECF 
accumulation occurs in more mature forms of NFTs and 
that the fragmentation of apoE is most likely a late event 
in the evolution of tangle pathology.  
Double-label confocal immunofluorescence studies 
using an antibody specific to the amino-terminal region of 
full-length apoE4 and nApoECF showed strong co-
localization in NFTs as well as blood vessels.  By contrast, 
application of a full-length antibody specific to the C-
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terminal end of apoE4 resulted in a lack of 
immunoreactivity in NFTs but strongly labeled blood 
vessels. These results confirm our previous findings in 
AD, and support the specificity of the nApoECF antibody 
to the amino-terminal fragment of apoE4 [21].  In 
comparison of our previous study that examined late-
onset AD cases we found a similar relationship between 
the presence of apoE fragmentation and its’ localization 
in NFTs of DS-AD cases. These data would suggest that 
the pathological events associated with apoE 
fragmentation in early onset-AD are similar when 
compared to late onset AD. 
In summary, we have documented the presence of an 
amino-terminal apoE fragment in both the frontal cortex 
and hippocampus of the DS-AD brain. The presence of 
this fragment within NFTs of DS-AD brain tissue 
suggests these two events may be causally linked.  
Previous studies support that harboring the APOE4 allele 
increases the risk for dementia in DS patients albeit to a 
lower extent to what has been found in AD.  The present 
findings suggest that apoE fragmentation is present within 
the DS brain and could provide a rationale as to the 
enhanced dementia risk associated with the APOE4 allele 
in DS. However, to best address this hypothesis, it would 
be necessary to compare autopsy cases with and without 
dementia, in addition to the presence or absence of AD 
neuropathology. Our data support a role for apoE 
proteolysis in DS-AD generating an amino-terminal 
fragment that accumulated with NFTs. Our study may 
provide impetus for further research on the potential 
impact of the APOE4 risk factor on dementia in older DS 
populations. 
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